IMPL
- Impel Pharmaceuticals Inc.
()
Overview
Company Summary
Impel Pharmaceuticals Inc. (IMPL) is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for central nervous system (CNS) diseases. They specialize in creating treatments that address the unmet medical needs of patients suffering from various neurological conditions.
IMPL's flagship product is known as INP104, which is a novel drug-device combination designed to treat migraines. INP104 utilizes a proprietary Precision Olfactory Delivery (POD) technology that efficiently delivers medications to the upper nasal cavity, providing rapid and targeted relief for migraine symptoms.
Apart from their migraine therapy, Impel Pharmaceuticals is also engaged in developing other drug-device combinations for various CNS disorders, such as Parkinson's disease, post-traumatic stress disorder (PTSD), and other conditions affecting the brain and nervous system.
The company's mission is to improve the lives of patients by providing effective and convenient treatments that enhance drug delivery and efficacy. Through their innovative drug-device technologies, IMPL aims to make a meaningful impact in the field of CNS therapeutics and improve patient outcomes.